Amicus Therapeutics (FOLD) to Start Enrollment of Phase 1/2 study of ATB200 in Pompe Disease
Tweet Send to a Friend
Amicus Therapeutics (Nasdaq: FOLD) announced that its investigational new drug (IND) application, submitted to U.S. Food and Drug Administration (FDA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE